Abstract

The Development Core will be co-directed by Drs Myron Levin and. Charles Dinarello. The primary purposeof the Development Core will be to allocate resources to augment AIDS research efforts at componentinstitutions. Emphasis will be placed on support for interdisciplinary projects and infrastructure investmentsthat will have a broad impact AIDS research capabilities, to recruit new investigators, to provide transitionalfunding to Junior Faculty and facilitate the-conduct of pilot studies.The Development Core will have three Specific Aims:A. To make major infrastructure or programmatic investments that will broadly facilitate interactions,capabilities, and/or efficiencies of the AIDS research community conducted by investigators at thecomponent institutions.B. To recruit outstanding new investigators with AIDS expertise to the faculties of the institution from outsideinstitutions or from training programs within the institution.C. To provide initial funding for pilot and feasibility studies. These funds might be used by juniorinvestigators, by established investigators to explore novel areas of AIDS research, or by excellentinvestigators not previously involved in AIDS research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI054907-05S1
Application #
7697494
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
2008-05-22
Project End
2009-04-30
Budget Start
2008-05-22
Budget End
2009-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$66,333
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Cook, Paul F; McElwain, Catherine J; Bradley-Springer, Lucy A (2016) Brief report on ecological momentary assessment: everyday states predict HIV prevention behaviors. BMC Res Notes 9:9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Haas, Michelle K; Levy, David N; Folkvord, Joy M et al. (2015) Distinct patterns of Bcl-2 expression occur in R5- and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo. AIDS Res Hum Retroviruses 31:298-304
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085

Showing the most recent 10 out of 95 publications